A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial, marking the company’s first late-stage readout. The drug, navacaprant, showed no significant improvement over placebo in reducing depression scores, with both groups experiencing a 12.5-point reduction. Additionally, it failed to demonstrate statistical significance on a pleasure-experience scoring system compared to the placebo group. This is one of three planned Phase 3 studies for navacaprant.
Source: https://www.statnews.com/2025/01/02/neumora-therapeutics-antidepressant-clinical-trial-data